- Home
- XYF vs MIST Comparison
XYF vs MIST Comparison
Compare XYF & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XYF | MIST |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.7M | 176.3M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | XYF | MIST |
|---|---|---|
| Price | $4.85 | $1.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 104.6K | ★ 1.3M |
| Earning Date | 05-18-2026 | 05-13-2026 |
| Dividend Yield | ★ 11.34% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,915.14 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.90 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.30 | $1.00 |
| 52 Week High | $20.36 | $3.06 |
Technical Indicators
Market Signals| Indicator | XYF | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 50.20 | 35.50 |
| Support Level | $4.48 | $1.20 |
| Resistance Level | $5.11 | $2.30 |
| Average True Range (ATR) | 0.21 | 0.07 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 28.99 | 27.27 |
Price Performance
Historical ComparisonAbout XYF X Financial each representing six
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, guarantee services provided and financing income.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).